Inhibition of autophosphorylation of epidermal growth factor receptor by a small peptide not employing an ATP-competitive mechanism
✍ Scribed by Mineo Abe; Yoshihiro Kuroda; Munetaka Hirose; Masaki Kato; Masahiro Murakami; Yoshihiko Watanabe; Minoru Nakano; Tetsurou Handa
- Publisher
- Wiley (John Wiley & Sons)
- Year
- 2008
- Tongue
- English
- Weight
- 546 KB
- Volume
- 89
- Category
- Article
- ISSN
- 0006-3525
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Previously we found that short peptides surrounding major autophosphorylation sites of EGFR (VPEY^1068^INQ, DY^1148^QQD, and ENAEY^1173^LR) suppress phosphorylation of purified EGFR to 30–50% at 4000 μ__M__. In an attempt to improve potencies of the peptides, we modified the sequences by substituting various amino acids for tyrosine or by substituting Gln and Asn for Glu and Asp, respectively. Among the modified peptides, Asp/Asn‐ and Glu/Gln‐substitution in DYQQD (NYQQN) and ENAEYLR (QNAQYLR), respectively, improved inhibitory potencies. The inhibitory potency of NYQQN was not affected by the concentration of ATP, while that of QNAQYLR was affected. Docking simulations showed different mechanisms of inhibition for the peptides: inhibition by binding to the ATP‐binding site (QNAQYLR) and inhibition by binding to a region surrounded by αC, the activation loop, and the catalytic loop and interfering with the catalytic reaction (NYQQN). The inhibitory potency of NYQQN for insulin receptor drastically decreased, whereas QNAQYLR inhibited autophosphorylation of insulin receptor as well as EGFR. In conclusion, NYQQN is not an ATP‐competitive inhibitor and the binding site of this peptide appears to be novel as a tyrosine kinase inhibitor. NYQQN could be a promising seed for the development of anti‐cancer drugs having specificity for EGFR. © 2007 Wiley Periodicals, Inc. Biopolymers 89: 40–51, 2008.
This article was originally published online as an accepted preprint. The “Published Online” date corresponds to the preprint version. You can request a copy of the preprint by emailing the Biopolymers editorial office at [email protected]